Fundacao Champalimaud ( Site 2200)

Lisbon 1400-038

1 studies enrolling now · 1 studies all time

What they study most

Triple-Negative Breast Cancer

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) — Recruiting now